Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test

Multiple Sclerosis affects around 700,000 people in Europe and 2.8 million worldwide.

It is the most common chronic neurological disease in young adults in developed countries, and the main cause of disability after traffic accidents.Current diagnosis process takes one year (on average) which makes pharmacological treatment start late producing irreversible damage in patients and a worse prognosis.

Combined with the high rate of misdiagnoses (20%), it leads to a healthcare cost of around 20 billion every year.ALA DIAGNOSTICS is revolutionising MS diagnosis with the first MS diagnostic kit, based on our patented recombinant protein, which is the only specific and clinically validated biomarker that exists for the diagnosis of MS in blood.

Our diagnostic test is fast, easy, cheap, non-invasive, suitable for early diagnosis of MS and easy to integrate into daily clinical routine.